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ABSTRACT 
Deep vein thrombosis (DVT) with its major complication, pulmonary embolism, is a 
global health problem. Mechanisms of DVT remain incompletely understood. Platelets 
play a role in DVT but the impact of specific platelet receptors remains unclear. Platelet 
C-type lectin-like receptor 2 (CLEC-2) is known to maintain the physiological state of 
blood vasculature under inflammatory conditions. DVT is a thromboinflammatory 
disorder developing largely as sterile inflammation in the vessel wall. We hypothesized 
therefore that CLEC-2 might play a role in DVT. Here, using a murine DVT model of 
inferior vena cava (IVC) stenosis, we demonstrate that mice with general inducible 
deletion of CLEC-2 or platelet-specific deficiency in CLEC-2 are protected against DVT. 
No phenotype in the complete stasis model was observed. Transfusion of wild-type 
platelets into platelet-specific CLEC-2 knockout mice restored thrombosis. Deficiency in 
CLEC-2 as well as inhibition of podoplanin, a ligand of CLEC-2, was associated with 
reduced platelet accumulation at the IVC wall after 6 h stenosis. Podoplanin was 
expressed in the IVC wall, where it was localized in the vicinity of the abluminal side of 
the endothelium. The level of podoplanin in the IVC increased after 48 h stenosis to a 
substantially higher extent in mice with a thrombus vs. those without a thrombus. 
Treatment of animals with an anti-podoplanin neutralizing antibody resulted in 
development of smaller thrombi. Thus, we propose a novel mechanism of DVT, 
whereby CLEC-2 and up-regulation of podoplanin expression in the venous wall trigger 
thrombus formation. 
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INTRODUCTION 
Platelets are responsible for primary hemostasis and are among the first cells arriving to 
the site of vascular injury. After adhesion to the exposed subendothelial proteins, such 
as collagen, and capture of von Willebrand factor (VWF), platelets become activated 
and develop a clot sealing the damaged vascular wall.  Platelet activation is initiated by 
various stimulatory ligands, such as ADP and collagen, which trigger a signaling 
cascade leading to conformational change in the integrin IIb3 (known as inside-out 
signaling).  
One mechanism of platelet activation is through receptors containing an 
immunoreceptor tyrosine-based activation motif (ITAM) or the structurally related 
(hem)ITAM. Murine platelets express one ITAM- and one (hem)ITAM-bearing receptors, 
GPVI and CLEC-2, respectively, whereas human platelets have an additional ITAM-
containing protein, FcRIIA. CLEC-2 is a receptor for podoplanin, which is expressed on 
various cell types including lymphatic endothelium and tumor cells, but is absent from 
the blood vascular endothelial cells.1,2 
CLEC-2 seems to play only a minimal role in normal hemostasis. One report 
demonstrated that CLEC-2 deficiency prolonged tail bleeding time,3 whereas others 
found an insignificant trend or no increase in blood loss.4-6  
In addition to their role in hemostasis, platelets participate in a number of non-
hemostatic processes. Platelets have been shown to maintain vascular integrity, 
regulate endothelial permeability and prevent hemorrhage at sites of inflammation in the 
vasculature.7-9 Hillgruber et al. found that breaching of the endothelial barrier by 
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neutrophils is a central mechanism of hemorrhage under thrombocytopenic conditions.10 
Recent studies demonstrated the critical role of GPVI and CLEC-2 in prevention of 
hemorrhaging induced by inflammation.11 Thus, platelet ITAM and hem(ITAM) receptors 
modulate the functional state of endothelium in inflammatory settings. 
Deep vein thrombosis (DVT) with its deadly complication pulmonary embolism (PE), 
designated together as venous thromboembolism (VTE), are a disastrous health 
problem. Hundreds of thousands of individuals develop VTE in the US annually and, 
despite new therapeutic modalities, the overall prevalence of VTE has not substantially 
decreased within last 2.5 decades.12,13 In contrast to arterial thrombosis, which is based 
on platelet accrual at the ruptured atherosclerotic plaque, the thrombosis in veins occurs 
without visible endothelial denudation or injury.14 One of the central triggering 
mechanisms of DVT (with the exception of cancer, trauma, or hereditary 
hypercoagulability-related venous thrombosis) is stagnancy of blood flow in venous 
valves, a part of the Virchow’s triad.15 Hypoxia developed as a result of flow distortion, 
may render the local environment even more prothrombotic. Blood inside valvular 
pockets has been shown to rapidly become hypoxic at static conditions with pO2 
returning back to luminal levels when flow is pulsatile.16 Hypoxia induces release of 
Weibel-Palade bodies (WPB), which are endothelial granules containing factors 
implemented in inflammation.17 We have recently demonstrated that release of WPB 
and cell recruitment to the vein endothelium is a crucial step in a murine model of 
DVT,18 whereas prevention of WPB liberation through the Scavenger Receptor B1 - 
eNOS pathway,19 protects against DVT in mice.20 In fact, DVT develops similarly to 
sterile inflammation starting with and depending on recruitment of immune cells and 
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platelets to the vessel wall.21 Consequently, venous thrombosis is tightly associated with 
inflammatory mechanisms and can be described as thromboinflammation.22 It is known 
that platelet depletion is protective in murine DVT,21 indicating the central role of 
platelets in this type of thrombosis. Thus, we hypothesize that platelet receptors, 
regulating functional properties of the vessel wall in inflammation, could play a role in 
DVT. 
In this study, we used a well-established DVT model of inferior vena cava (IVC) 
stenosis, mimicking blood flow distortion in venous valves, to study the role of CLEC-2 
venous thrombosis. In this model, thrombosis is triggered by endothelial activation in the 
absence of endothelial denudation or visible injury.21,23,24 We demonstrate a critical role 
of CLEC-2 in DVT with complete protection of inducible knockout mice and partial 
protection of platelet-specific knockouts. No phenotype in the complete stasis model 
was observed. The CLEC-2 ligand podoplanin was expressed in the IVC wall, 
upregulated during thrombosis, and its pharmacological inhibition decreased DVT 
thrombus size. These results demonstrate that targeting CLEC-2 could be beneficial for 
prophylaxis of DVT in the absence of major effect on hemostasis. 
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METHODS 
Mice  
All animal experimentation was performed after ethical approval from Animal Welfare 
Ethical Review Body and the UK Home Office (Project Licenses 70/8286 and 40/3745). 
Mice 7-10 weeks old of both genders were used. All mice were on C57BL/6 
background. For inducible deletion of CLEC-2 expression, 4-5 week-old Clec1bfl/fl × 
Rosa26+/ERT2cre mice and their Clec1bfl/fl x Rosa26+/+ control littermates were fed with 
tamoxifen-supplemented diet TAM 400 (400 mg tamoxifen in citrate form per Kg of diet, 
Harlan, UK) for 2 weeks, followed by 4 weeks of regular diet.as previously described.25 
Clec1bfl/fl Pf4Cre+ mice (platelet-specific CLEC-2 deletion) have been described 
elsewhere.26 Vav1Cre+ pdpnfl/fl (hematopoietic cell-specific knockout) and Tie2Cre+ pdpnfl/fl 
(knocks out podoplanin in cells of endothelial origin) mice were created by crossing 
pdpnfl/fl animals with Vav1cre+ mice27 and Tie2cre+ mice (Jackson Lab, strain 008863), 
respectively. Podocin-cre pdpnfl/fl mice were created in house by crossing pdpnfl/fl 
animals with podocincre+ (Jackson Lab, stock number 008205) mice. 
 
Flow restriction in the inferior vena cava (IVC): a model of DVT in mice 
The established flow restriction (stenosis) model of DVT was performed as described 
previously.18 Mice were anesthetized using isoflurane, placed in a supine position, and 
attached to a mask with a constant flow of anesthetics. An incision was made along the 
midline of the abdomen and the guts exteriorized. Saline was applied to the guts 
regularly throughout the experiment to prevent drying out. The IVC was gently 
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separated from the aorta. Any side branches were closed using a 7.0 polypropylene 
suture. To achieve stenosis (partial flow restriction) the IVC was ligated over a 30-gauge 
needle or ‘spacer’. The suture was tied over the spacer and then the spacer was 
removed. This procedure achieves ~90% closure of the vessel lumen but doesn’t cause 
endothelial injury. The peritoneum was then closed using a 6.0 suture, and the skin was 
stapled back together. After 48 hours, the mice were culled and the thrombi, if they 
developed in the IVC, were taken for analysis. Thrombosis prevalence in WT mice in 
this model is 65 – 100% after 48 h IVC stenosis.18,28 
The rodent stasis model of DVT has been described elsewhere.29,30 In brief, the IVC as 
well as side branches were completely ligated, whereas back branches were 
cauterized. Thrombus development was checked after 24 h. 
 
Transfusion of WT platelets into Clec1bfl/fl Pf4-Cre mice. 
Blood was collected from the retro-orbital plexus of WT C57Bl/6 mice, stabilized by 
sodium citrate and centrifuged at 100 g for 5 min to obtain platelet rich plasma (PRP). 
Red blood cells were sedimented by centrifugation (100 g; 3.5 min), the supernatant 
(PRP) was incubated with prostaglandin I2 (2 g/ml, 5 min, 37C) and centrifuged (1000 
g, 5 min). Platelet pellet was resuspended in modified Tyrode’s buffer (134 mM NaCl, 
2.9 mM KCl, 0.34 mM Na2HPO412H2O, 12 mM NaHCO3, 20 mM HEPES, 1 mM MgCl2, 
5 mM glucose, pH 7.35). After pooling platelets from a number of donor mice, platelets 
(8 x 108 in 200 l of buffer) were infused into recipient Clec1bfl/fl Pf4Cre+ mice through the 
tail vein. Transfusion of this amount of platelets results in recovery of more than 50% of 
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circulating platelets.11 Immediately after that, recipient mice were subjected to IVC 
stenosis, and thrombus formation was checked after 48 h. 
 
Treatment of mice with anti-podoplanin antibody 
In the DVT experiments, WT littermates were injected with anti-podoplanin antibody 
(Syrian hamster anti-mouse, clone 8.1.1) twice: 24 h and 30 min before surgery (100 
g/mouse and 50 g/mouse, i.v., respectively). In the intravital microscopy experiments, 
WT littermates received one injection of the antibody (100 g/mouse) immediately 
before surgery. Control mice received injection of the same dose of IgG. This antibody 
has been shown to block podoplanin in mice for at least 48 h at a dose of 100 
g/mouse.31 Specificity of the antibody was proven by abundant staining of podoplanin 
in kidneys of WT animals and absence of staining in mice with tissue-specific 
podoplanin deficiency (Suppl. Figure 1).  
 
Intravital microscopy of the IVC and calculation of the area covered with adhered 
platelets 
Mice underwent IVC stenosis and allowed recover consciousness. In 6 h, mice were 
anesthetized using tribromethanol as described above and syngeneic washed platelets 
(2.5% of the total number of circulating platelets) labeled with calcein AM were injected 
intravenously. The mouse was placed into the supine position and the IVC was exposed 
and covered with a round coverslip. Fluorescent platelets in the IVC were visualized by 
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a 3i VIVO-SDC confocal system with Yokogawa CSU-10 and Photometrics Evolve 
EMCCD camera on an Olympus BX61WI upright microscope with air objective x10. 
Focus was adjusted to the upper focal plane. Platelets were visualized 1-2 mm below 
the suture (in caudal direction) and recorded for at least 1 min. Fiji/ImageJ32 was used 
to quantify areas of adhered platelets. Median-based intensity projection from 10 
randomly chosen consecutive acquired images (corresponding to 1 s) was utilized to 
generate a single (median) projected image. After automatic set of threshold, total area 
of adhered platelets was measured by a Fiji incorporated function “Analyze particles”. 
 
Western blotting 
IVC were collected from non-operated mice or from mice after DVT surgery and lysed. 
DVT thrombi were separated from IVC and lysed. Fifty microgram of total protein were 
loaded per lane and separated in SDS-PAGE. Protein gels were blotted to PVC 
membranes in Turbo Blot Transfer system, blocked with 3% BSA and developed using 
following primary antibodies: hamster anti-mouse PDPN (eBioscience, clone 8.1.1), 
mouse anti-tubulin (Sigma). Densitometry of bands was performed and the result was 
normalized to the density of the corresponding tubulin band. 
 
Immunohistochemistry 
DVT thrombi including adjacent IVC were collected and fixed in formalin. Tissue was 
frozen in OCT. Cryosections (10 m thick) were blocked in 5% NGS, 1% BSA without 
permeabilization and stained using primary antibodies: hamster anti-mouse PDPN 
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(eBioscience), rabbit anti-human VWF (DAKO), following by Alexa-Fluor labeled 
secondary antibodies (Molecular probes). Nuclei were stained by ToPro3. Confocal 
images were taken by Leica confocal microscope using company software. Scanning of 
the whole thrombus was performed using Axio Scan.Z1 (Zeiss). Images were evaluated 
by Fiji/ImageJ.32 
 
Statistics and power calculation 
The sample size estimation was performed using G*Power 3.1.9.2.33 Based on our 
current experience with the model at the University of Birmingham, thrombi prevalence 
in control mice after 48 h IVC stenosis varies between 60 – 100%. Therefore, we 
assumed the expected difference (effect size) between experimental groups to be at 
least 0.8, error probability of 0.1 and the desired power value of 0.80. The calculated 
sample size for DVT experiments was 15 animals per group. 
Non-parametric data (weight and length of thrombi) were compared using the Mann-
Whitney test. Parametric results (area covered by platelets in the intravital microscopy 
of the IVC) were compared using two-tailed Student’s t-test. Thrombosis prevalence 
was compared by the Fisher’s exact square method. Difference was considered 
significant at p<0.05.   
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RESULTS 
CLEC-2 exacerbates DVT  
To address the impact of CLEC-2 in venous thrombosis we utilized a model of IVC 
stenosis. Forty eight hours after stenosis application, mice with a post-development 
inducible loss of CLEC-2 were completely protected from DVT with none of the mutant 
mice producing a thrombus as compared with 60% of mice in the littermate control 
group (Figure 1A). This frequency of thrombosis is similar to previous reports using this 
model and mouse strain (C57BL/6), where it ranges from 60 – 100%. To test the 
potential role of platelet CLEC-2, we subjected platelet-specific knockout mice and 
littermate controls to IVC stenosis. Prevalence of thrombi comprised 81% in controls vs. 
38% in knockouts (p < 0.05; Figure 1B). Transfusion of WT platelets (to approximately 
50% of circulating platelets) restored thrombosis, which further supports the importance 
of platelet CLEC-2 in DVT. No phenotype was observed in the stasis model (data not 
shown). Thus, CLEC-2, and platelet CLEC-2 in particular, is critically important for DVT 
development in the model of partial occlusion.  
 
Mice lacking CLEC-2 have a reduced level of platelet recruitment to the vessel 
wall  
Endothelial activation and resulting accrual of platelets and immune cells in the vicinity 
to the vessel wall is a central event in DVT development.18,21 We used intravital 
microscopy of the IVC 6 h after stenosis application to assess recruitment of platelets. 
In WT controls, adhered platelets covered the area of 7.8 ± 0.7% of the view field 
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(Figure 2A, Suppl. movie 1). In contrast, in mice lacking CLEC-2, most of the platelets 
did not attach firmly to the IVC wall and detached in the direction of blood flow (Figure 
2A, Suppl. movie 2). The average area covered by adhered platelets in these mice was 
1.3 ± 0.4% (Figure 2B, P < 0.003). Inhibition of podoplanin by a specific neutralizing 
antibody resulted in a similar phenotype (6.5 ± 1.3% in IgG controls vs. 2.6 ± 0.4% after 
antibody administration; P < 0.03; Figure 2C-D; Suppl. movies 3 and 4). This result 
implies that CLEC-2 and podoplanin expression is a prerequisite for platelet recruitment 
possibly through direct binding and by potentiating endothelial activation and Weibel-
Palade body release. 
 
IVC vessel wall expresses podoplanin  
Given that the lack of CLEC-2 and inhibition of podoplanin produce a similar phenotype 
in terms of cell recruitment, we next asked whether podoplanin is expressed in the IVC 
wall. Immunostaining revealed a minor podoplanin signal in the wall of sham-operated 
IVC (Figure 3A i). Microscopy with identical settings revealed that podoplanin 
expression in thrombosed IVC was substantially elevated (Figure 3A ii). Podoplanin was 
expressed exclusively in the vessel wall (not in the thrombus; Figure 3B) and localized 
in the vicinity to the abluminal side of the endothelium (Figure 3C i) recognized by 
positivity for PECAM-1 (CD31). At the used microscopy settings, no podoplanin signal 
was observed in thrombi, which could be identified by staining for VWF (Figure 3C ii). 
Platelets penetrated the vessel wall during DVT and had therefore an opportunity to 
interact with subendothelial matrix components including podoplanin (Figure 3D). 
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The presence of podoplanin in the vascular wall was confirmed by Western blotting. 
Podoplanin was absent in 4 out of 5 thrombi (Figure 4A), with the presence at trace 
level in the fifth thrombus, probably due to remnants of the vessel wall. Podoplanin was 
detected in the sham-operated IVC (that had not undergone stenosis) (Figure 4B, three 
left lanes). Application of stenosis for 48 h, resulting in thrombosis, increased 
podoplanin expression in the IVC wall from 3.6 ± 1.3 to 33.4 ± 8.3 arbitrary units (a.u., P 
< 0.004, Figure 4C) as measured by band densitometry normalized to corresponding 
tubulin loading control. Interestingly, application of stenosis for the same period of time 
but without thrombus formation at the end, was accompanied by a much smaller 
increase in podoplanin expression to 14.3 ± 4.7 a.u (p = 0.053 vs. intact IVC). Thus, 
podoplanin expression in the IVC wall is increased during flow restriction, and amplitude 
of this increase corresponds to the degree of thrombosis. 
 
Anti-podoplanin antibody decreased size of thrombi in DVT 
In order to evaluate the role of podoplanin in DVT, we treated mice with an anti-
podoplanin blocking antibody (clone 8.1.1).31 The antibody did not affect DVT 
prevalence (82% in the antibody-treated mice vs. 90% in littermate control mice treated 
with IgG, Figure 5). As no difference was observed in the percent of mice carrying 
thrombi, we compared the size of thrombi. Both the weight and the length of thrombi 
were significantly lower in the group of animals treated with the antibody. This result 
suggests that CLEC-2 major ligand podoplanin in the vessel wall is implicated in DVT 
initiation. 
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DISCUSSION 
Our study demonstrates a pivotal role of CLEC-2 and in particular platelet CLEC-2 in 
thrombosis. We report that the total lack of CLEC-2 mediates complete protection 
against DVT, whereas absence of the receptor specifically on platelets results in partial 
but significant protection. Inducible knockouts Clec1bfl/fl x Rosa26+/ERT2Cre do not have 
visible vasculature defects compared with litter-mate controls (S.P.W. unpublished 
data). Neutrophils have been reported to express CLEC-2 in one34 but not another 
study.25 The finding that platelet-specific knockout mice have decreased thrombosis 
suggests a predominant role of CLEC-2 on platelets in DVT initiation. The reason for 
different median thrombus size in the WT (Cre- littermates) groups of Clec1bfl/fl x 
Rosa26+/- and Clec1bfl/fl Pf4Cre+ is unclear. It might be due to different transgenes that 
these mice carry or tamoxifen treatment or genetic drift due to the lack of cross-
breeding between the colonies for years.  
It is known that platelet-specific CLEC-2 knockouts have blood-lymphatic mixing and it 
is tempting to hypothesize that it may contribute to the lack of thrombosis. However, the 
post-development inducible knockouts do not have such a defect and have a phenotype 
even stronger than the platelet-specific knockouts. Also, transfusion of wild-type 
platelets into the Clec1bfl/fl Pf4Cre+ mice restores DVT despite the remaining blood-
lymphatic mixture. Thus, it is unlikely that the blood-lymphatic defect affects DVT. 
It is known that the functional state of endothelium, a component of Virchow’s triad, is 
central in the DVT pathogenesis. We previously demonstrated that proinflammatory shift 
in the endothelium, including release of WPB and recruitment of platelets and 
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leukocytes to the vessel wall, are critical for DVT initiation.18,21 Therefore, mechanisms 
of DVT initiation and development are similar to aseptic inflammation. Platelets are 
predominantly recruited through VWF, a WPB constituent.35 Deficiency in CLEC-2 
prevents platelet accrual to the IVC wall after several hours of stenosis and before 
thrombus is formed (Figure 2A-B and Suppl. movie 1 and 2). This implies that platelets, 
in a CLEC-2-dependent fashion, directly interact with the vessel wall and that this 
interaction is required for their recruitment and thrombosis initiation. Stenosis produces 
elevated blood pressure and formation of a “bulb” with highly distorted flow of low rate. 
This may create local hypoxia, which, similarly to other tissues,36 might upregulate 
podoplanin expression in the vessel wall. Hypoxia may also render the endothelial cell-
cell junctions looser and open allowing for platelet CLEC-2 interaction with podoplanin 
and, possibly, with other ligands that are yet to be characterized. Indeed, stenosis 
facilitates infiltration of the IVC wall with platelets, during which interaction of CLEC-2 
with podoplanin or another ligand may take place promoting thrombus formation. 
Clarification of the mechanisms of platelet egression to the vascular wall in the course 
of DVT requires further investigation. Podoplanin upregulation can not only be a cause 
for thrombosis but might also be triggered by thrombus formation or both mechanisms 
may operate in parallel forming a positive feedback. 
Interestingly, the anti-thrombotic phenotype was observed only in the partial occlusion 
(stenosis) model, whereas no difference in thrombosis prevalence and/or thrombus size 
occurred in the complete stasis model. It is possible that a pro-inflammatory shift playing 
a central pathogenetic role in partial occlusion is less important in full stasis in which 
thrombosis is initiated by tissue factor-driven blood coagulation.37   
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It has been reported that platelets contribute to maintenance of vascular integrity under 
inflammatory conditions7 through GPVI and CLEC-2.11 Therefore, CLEC-2 is able to 
modify functional properties of the endothelium, which might be relevant to DVT 
development. A similar unique impact of CLEC-2 has been demonstrated in Salmonella 
infection-induced thrombosis and this is independent of GPVI.38 Marked upregulation of 
podoplanin in the IVC wall induced by stenosis may promote its interaction with CLEC-
2. The importance of the extent of podoplanin expression elevation following stenosis is 
confirmed by direct association between the magnitude of this elevation and incidence 
of thrombosis.  
Given that DVT can be considered a model of thromboinflammation, the prothrombotic 
effect of CLEC-2 may be mediated by neutrophils. Flow restriction in the IVC increases 
expression of various trafficking agents, such as CCL2 and CXCL1, attracting and 
activating neutrophils.21 Leukocytes are recruited to the IVC wall at the early stages of 
DVT, and platelets potentiate this recruitment. Neutrophils release Neutrophil 
Extracellular Traps (NETs),39 which provide a surface for activation of coagulation factor 
XII and form a scaffold in addition to fibrin thus stabilizing the thrombus.21,40 Neutrophils 
also release metalloproteinases and other enzymes that can rearrange vessel wall 
rendering it more attractive for platelet recruitment.9 Down-regulated platelet 
accumulation at the stenosed IVC wall in the absence of CLEC-2 could impair leukocyte 
recruitment and thus contribute to the protection against thrombosis.  
DVT can be considered a thromboinflammatory process rather than pure thrombosis. 
The key role of CLEC-2 in thrombosis in inflammatory settings has recently been 
reported.38 This study demonstrated that after infection with Salmonella, extensive 
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thrombosis develops in the liver of control mice through an inflammation driven pathway 
in a CLEC-2-dependent fashion. Thrombosis induced by the bacteria was associated 
with up-regulation of podoplanin. Both these findings and our results demonstrate 
important role of CLEC-2 in thrombosis under either septic or aseptic inflammatory 
conditions, presumably due to upregulation of podoplanin. 
At present, podoplanin is the only known natural ligand for CLEC-2. Its expression has 
been confirmed in lymphatic endothelium, glomerular podocytes in kidneys, type I 
alveolar cells in lungs and in several types of cancers, but not in vascular endothelium.2 
However, up-regulation of podoplanin in the tissues adjacent to blood vasculature has 
been reported in the salmonella-mediated inflammation model38 and CLEC-
2/podoplanin interactions have been shown to secure vessel wall in high endothelial 
venules.41 We demonstrate here that podoplanin is present in the IVC wall. It is 
localized immediately below the endothelium and is dramatically up-regulated following 
stenosis of the IVC. This up-regulation was substantially higher in those IVCs that had 
thrombi compared to IVCs, in which, despite stenosis, no thrombi developed. It can be 
speculated that exposure to podoplanin in the vessel wall triggers platelet accrual and 
activation which, in turn, may further up-regulate podoplanin expression. This 
suggestion is further supported by direct observation of reduced platelet accumulation 
after anti-podoplanin antibody administration. As podoplanin is located at the abluminal 
side of the endothelium, the mechanism of antibody penetration through endothelial 
monolayer remains to be elucidated. It is possible that, under the conditions of elevated 
blood pressure and stretched vessel wall, gaps between endothelial cells become 
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looser, which makes contact between the antibody and podoplanin in the vessel wall 
possible.42,43 Thus, podoplanin in the venous wall contributes to DVT propagation. 
Direct evidence of podoplanin involvement in exacerbation of DVT was obtained in 
experiments with an anti-podoplanin antibody. Administration of the antibody 8.1.1 
resulted in smaller size of thrombi whereas the percent of mice producing thrombi 
remained the same. Thus, the absence of CLEC-2 and inhibition of podoplanin do not 
produce identical phenotypes in DVT and it cannot be unambiguously concluded that 
they operate as receptor-ligand couple. However, as podoplanin binding to CLEC-2 
activates platelets, it cannot be excluded that when podoplanin is neutralized, platelets 
still interact with the vessel wall through other mechanisms but their activation is 
impaired, which results in limited ability to support thrombus growth. Another possibility 
is that, in addition to podoplanin, another CLEC-2 ligand is involved to mediate 
complete absence of thrombi observed in CLEC-2-null mice. Incomplete blockage of 
podoplanin by the antibody in vivo, which precludes downregulation of thrombosis 
prevalence, also cannot be ruled out.  
The source of podoplanin in the IVC remains to be defined. It is unlikely to be 
hematopoietic or endothelial cell-derived as mice lacking podoplanin specifically in 
these cells retained podoplanin expression in the vessel wall and had no phenotype in 
DVT (Suppl. Figures 2 and 3). The ubiquitous layer-like pattern of staining and the 
presence of podoplanin in Tie2-Cre pdpnfl/fl mice rules out lymphatic vessels and nodes 
as a potential source of podoplanin. Fibroblastic reticular cells that surround high 
endothelial venules have been shown to be rich in podoplanin.41 Podoplanin is also 
expressed on myofibroblasts of the prostate and cultured normal and cancer-associated 
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fibroblasts.2,44,45 Therefore, it might be supposed that podoplanin in the vein wall 
originates from cells of fibroblastic nature. Vascular smooth muscle cells (VSMC) 
express another potential CLEC-2 ligand, S100A13.46 S100A13 becomes expressed on 
VSMC subjected to oxidative stress, which may be present in the IVC as a result of 
local hypoxia due to stenosis. However, it is not likely that this mechanism is involved in 
our experiments because venous wall, in contrast to arterial, does not contain 
substantial amounts of VSMC. 
In conclusion, we have demonstrated a major impact of both CLEC-2 and podoplanin in 
DVT. Total deficiency in CLEC-2 completely protects mice against DVT, whereas the 
lack of platelet CLEC-2 mediates partial though significant protection. Vein wall 
expresses podoplanin and it is implicated in venous thrombosis although to what extent 
it operates through CLEC-2 remains to be defined. Given that CLEC-2-null mice have 
only minimally impaired normal hemostasis, this receptor may be a potential target for 
DVT prophylaxis. 
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FIGURE LEGENDS 
Figure 1. CLEC-2 exacerbates DVT in mice. 
(A) Clec1bﬂ/ﬂxRosa26+/creERT2 (n=10) and their Clec1bﬂ/ﬂ littermates (n=9) after 2 weeks 
of tamoxifen diet followed by 4 weeks of normal diet or (B) Clec1bfl/fl Pf4-Cre mice 
(n=13) and control littermates (n=11) were subjected to IVC stenosis for 48 h. Some of 
Clec1bfl/fl Pf4-Cre mice were transfused with 8 x 108 WT platelets prior to surgery. 
Panels i, ii and iii show thrombus weight, thrombus length and thrombosis prevalence, 
respectively. Lines in dot plots represent median. Note restoration of thrombosis after 
transfusion of WT platelets. 
 
Figure 2. Stenosis-induced platelet recruitment is reduced in the absence of CLEC-2 or 
after neutralization of podoplanin.  
IVC stenosis was applied to Clec1bﬂ/ﬂxRosa26+/creERT2 and their Clec1bﬂ/ﬂ littermates for 
6 h. Fluorescently labeled syngeneic platelets were infused and their deposition on the 
IVC wall was visualized by intravital microscopy. A, representative averaged images of 
adhered platelets (bright white); B, percent of area covered by immobilized platelets, 
n=3 to 4. Data are presented as mean ± SEM. C, the same experimental design was 
applied to WT mice injected with anti-podoplanin neutralizing antibody (100 g/mouse, 
i.v.) or IgG control before surgery. D, percent of area covered by recruited platelets; n = 
4 for both groups. 
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Figure 3. Podoplanin is expressed in the IVC vessel wall. 
Sham-operated IVC (A i) or 48 stenosis-induced thrombi together with the IVC (Aii, B 
and C) were excised and stained for podoplanin (green) and PECAM-1 (A i and ii, Ci; 
red) or VWF (C ii, red). Nuclei are blue in all images. A i and ii, sham-operated IVC and 
IVC with a thrombus, respectively, photographed under identical microscope settings. 
Note increased podoplanin expression in the thrombosed IVC. B, whole thrombus after 
48 h of stenosis within the IVC. C i and ii, co-staining of podoplanin with PECAM-1 and 
VWF, respectively. Note podoplanin localization below the endothelium and absence of 
podoplanin in the thrombus. D, staining of IVC with a thrombus after 48 h stenosis for 
podoplanin (green) and platelets (CD41, red). Note platelets penetrating the vessel wall 
and localizing in the vicinity to podoplanin. A, bar is 50 m; B, bar is 500 m; C, bar is 
100 m; n = 4 - 5. D, bar is 10 m, Representative images of n = 3 with 10-15 images 
from each IVC. T, thrombus, L, lumen. 
 
Figure 4. Expression of podoplanin in the IVC vessel wall increases with thrombosis. 
A-C, Thrombi and the IVC were taken separately for Western blotting. A, Western blot 
of 5 thrombi vs. 1 IVC after 48 h stenosis. Note complete absence of podoplanin in 4 out 
of 5 thrombi and abundant podoplanin signal in the IVC; B, intact IVCs (lanes 1-3), IVCs 
after stenosis with thrombi (St+T, lanes 4-6), IVC after stenosis without thrombi (St N/T, 
lanes 7-9). Loading is confirmed by blotting for tubulin. C, densitometry of podoplanin 
26 
 
bands normalized to tubulin; data in bar graph represent mean ± SD; n = 6 for each 
group.  
 
Figure 5. Anti-podoplanin antibody decreases size of thrombi in murine DVT. 
Wild-type mice were injected with neutralizing anti-podoplanin antibody (clone 8.1.1) 24 
h (100 g/mouse) and 30 min (50 g/mouse) prior to surgery and then subjected to IVC 
stenosis for 48 h. Control mice were administered isotype-matched IgG. Presented are 
(left to right): thrombus weight, length and thrombosis prevalence. Lines in dot plots 
represent median. N=10 (for IgG) and 11 (for the antibody). 
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